Abstract:Purpose: To examine the effects of serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1) on choroidal structures with different blood glucose levels in patients with diabetes mellitus (DM) with acromegaly without diabetic retinopathy. Methods: Eighty-eight eyes of 44 patients with acromegaly were divided into a nondiabetic group (23 patients, 46 eyes) and a diabetic group (21 patients, 42 eyes). Forty-four age- and sex-matched healthy controls and 21 patients with type 2 DM without diabetic retinopathy were also included. Linear regression models with a simple slope analysis were used to identify the correlation and interaction between endocrine parameters and choroidal thickness (ChT), total choroidal area (TCA), luminal area (LA), stromal area (SA), and choroidal vascular index (CVI). Results: Our study revealed significant increases in the ChT, LA, SA, and TCA in patients with acromegaly compared with healthy controls, with no difference in the CVI. Comparatively, patients with DM with acromegaly had greater ChT than matched patients with type 2 DM, with no significant differences in other choroidal parameters. The enhancement of SA, LA and TCA caused by an acromegalic status disappeared in patients with diabetic status, whereas ChT and CVI were not affected by the interaction. In the diabetic acromegaly, higher IGF-1 (P = 0.006) and GH levels (P = 0.049), longer DM duration (P = 0.007), lower blood glucose (P = 0.001), and the interaction between GH and blood glucose were associated independently with thicker ChT. Higher GH levels (P = 0.016, 0.004 and 0.007), longer DM duration (P = 0.022, 0.013 and 0.013), lower blood glucose (P = 0.034, 0.011 and 0.01), and the interaction of IGF-1 and blood glucose were associated independently with larger SA, LA, and TCA. As blood glucose levels increased, the positive correlation between serum GH level and ChT diminished, and became insignificant when blood glucose was more than 7.35 mM/L. The associations between serum IGF-1 levels and LA, SA, and TCA became increasingly negative, with LA, becoming significantly and negatively associated to the GH levels only when blood glucose levels were more than 8.59 mM/L. Conclusions: Acromegaly-related choroidal enhancements diminish in the presence of DM. In diabetic acromegaly, blood glucose levels are linked negatively with changes in choroidal metrics and their association with GH and IGF-1. Translational relevance: We revealed the potential beneficial impacts of IGF-1 and GH on structural measures of the choroid in patients with DM at relatively well-controlled blood glucose level, which could provide a potential treatment target for diabetic retinopathy.

Effects of active acromegaly on bone mRNA and microRNA expression patterns.

The Negative Impacts of Acromegaly on Bone Microstructure Not Fully Reversible

New insights into the metabolic-bone crosstalk in active acromegaly

[Effects of Recombinant Human Growth Hormone (GH) Replacement Therapy on Bone Metabolism in Children with GH Deficiency].

Gene Expression Signature in Adipose Tissue of Acromegaly Patients

Decreased Serum Wnt Antagonist Levels in Patients with Active Acromegaly

The comprehensive impact on human body induced by resolution of growth hormone excess.

The Change of Bone Turnover Markers and Bone Remodelling Balance in Acromegaly

OR32-5 Associations between Circulation Lipocalin 2, Body Composition, and Glucose Metabolism in Active Acromegaly

Effects of somatostatin receptor ligands on bone metabolism in acromegaly

Associations Between Circulating Bone-Derived Hormones Lipocalin 2, Osteocalcin, and Glucose Metabolism in Acromegaly.

Effects of endogenous hypercortisolism on bone mRNA and microRNA expression in humans

Excess Growth Hormone Triggers Inflammation-Associated Arthropathy, Subchondral Bone Loss, and Arthralgia

Influence of disease activity and gonadal status on bone mineral density and turnover in acromegaly

Surgical Outcomes and Predictors of Glucose Metabolism Alterations for Growth Hormone-Secreting Pituitary Adenomas: a Hospital-Based Study of 151 Cases.

Association Between Growth Differentiation Factor 15 (GDF15) and Glucose Metabolism in Patients With Acromegaly

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Advances in drug treatment of acromegaly

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly

Blood Glucose Levels Moderate the Associations Between IGF-1 Levels and Choroidal Metrics in Patients With Diabetes With Acromegaly Without Diabetic Retinopathy

Acromegaly: The Relationship between Hemodynamic Profiles Assessed via Impedance Cardiography and Left Ventricular Systolic Function Assessed via Echocardiography